Kodiak Sciences (KOD) added ~33% in the premarket on Thursday after the company announced that a Phase 3 trial for its eye ...

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced positive ...

By Siddhi Mahatole March 26 (Reuters) - Shares of Kodiak Sciences surged 68.6% to their highest in more than four years on ...

Shares of Kodiak Sciences surged sharply on Thursday after the biotechnology company reported positive results from a ...

U.S. AI-driven Diabetic Retinopathy Screening Market · GlobeNewswire Inc. The U.S. AI-driven diabetic retinopathy screening ...

AI-based screening for glaucoma can be implemented in primary care within existing screening programmes, enhancing efficiency ...

Biggest stock gainers. Kodiak Sciences +54% – Shares soared after the company reported positive Phase 3 data for its eye ...

Cataract surgery was associated with an increased risk of worsening diabetic retinopathy in adults with type 2 diabetes. Diabetes is a risk factor for complications due to cataract surgery. Patients ...

STOCKHOLM — At the American Society of Retina Specialists (ASRS) 2024 Annual Meeting, researchers discussed how insights into potential risk factors and new treatments could improve outcomes for ...

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing ...

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving ...